Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Will Regeneron's COVID Cocktail Win Be Short-Lived?

TheMotleyFool

0 0

Will Regeneron's COVID Cocktail Win Be Short-Lived?Photo, wide shot, wide-angle lens, Biotech company, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Sebastião Salgado: https://img.theapi.app/temp/80e18bfd-1ff8-4487-af62-1cdb7de1ceb6.png

Regeneron Pharmaceuticals (NASDAQ: REGN) recently racked up a couple of additional successes with late-stage studies of its COVID-19 antibody cocktail REGEN-COV. In this Motley Fool Live video recorded on April 14, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether the biotech's COVID cocktail win will only be short-lived.

Source Fool.com

Like: 0

REGN

Share